Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Sees Significant Growth in Short Interest

Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) saw a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 5,179 shares, a growth of 154.7% from the June 30th total of 2,033 shares. Based on an average trading volume of 869 shares, the short-interest ratio is presently 6.0 days.

Algernon Pharmaceuticals Price Performance

AGNPF opened at $0.29 on Monday. The business has a fifty day simple moving average of $0.31 and a 200-day simple moving average of $0.16. Algernon Pharmaceuticals has a fifty-two week low of $0.23 and a fifty-two week high of $0.64.

Algernon Pharmaceuticals Company Profile

Algernon Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.

The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF).